Back
Leggett & Platt 10K Form
Sell
22
LEG
Leggett & Platt
Last Price:
12.27
Seasonality Move:
4.42%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-08 | 10Q | LEG/Leggett & Platt Quarterly |
2024-02-27 | 10K | LEG/Leggett & Platt Annual |
2023-11-07 | 10Q | LEG/Leggett & Platt Quarterly |
2023-08-08 | 10Q | LEG/Leggett & Platt Quarterly |
2023-05-04 | 10Q | LEG/Leggett & Platt Quarterly |
2023-02-24 | 10K | LEG/Leggett & Platt Annual |
Receive LEG News And Ratings
See the #1 stock for the next 7 days that we like better than LEG
LEG Financial Statistics
Sales & Book Value
Annual Sales: | $4.73B |
---|---|
Cash Flow: | $78.5M |
Price / Cash Flow: | 5.82 |
Annual Sales: | $4.98 |
Price / Book: | 2.48 |
Profitability
EPS (TTM): | -5.95000 |
---|---|
Net Income (TTM): | $-815.1M |
Gross Margin: | $853.8M |
Return on Equity: | -61.79% |
Return on Assets: | -17.48% |
Leggett & Platt Earnings Forecast
Key Leggett & Platt Financial Ratios
- The Gross Profit Margin over the past 40 years for LEG is 18.07%.
- The Selling, General & Administrative Expenses for LEG have been equal to 9.85% of Gross Profit Margin.
- The Research & Development expenses have been 0.00% of Revenue.
- The Interest Expense is -64.62% of Operating Income.
- The Net Earning history of LEG is -2.90% of Total Revenues.
- Per Share Earnings over the last 40 years have been positive in 24 years.
Leggett & Platt Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | S&P500 |
---|---|
Industry: | Household Durables |
Sector: | Consumer Discretionary |
Current Symbol: | LEG |
CUSIP: | 524660 |
Website: | leggett.com |
Debt
Debt-to-Equity Ratio: | 3 |
---|---|
Current Ratio: | 1.53 |
Quick Ratio: | 0.82 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 9.63 |
LEG Technical Analysis vs Fundamental Analysis
Sell
22
Leggett & Platt (LEG)
is a Sell
Is Leggett & Platt a Buy or a Sell?
-
Leggett & Platt stock is rated a Sell
The current Leggett & Platt [LEG] share price is $12.30. The Score for LEG is 22, which is 56% below its historic median score of 50, and infers higher risk than normal.